An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors
An extension study of linifanib in subjects with advanced or metastatic solid tumors.
Advanced Solid Tumors
DRUG: linifanib
Safety: Adverse Events - The number of participants with adverse events will be reported as a measure of Safety., The investigators will monitor each subject for clinical and lab evidence of adverse events on a routine basis through out the study. The investigators will question each subject regarding any adverse effects that they have experienced and record any events on the care report forms. All adverse events will be followed to a satisfactory clinical resolution., All adverse events occuring through the Final Visit will be reported.|Safety: Physical Examination and Vital Signs - Physical examination will be performed and vital signs will be assessed for participants as a measure of safety., Physical exam, blood pressure, pulse, body temperature will be measured and recorded on the case report forms., Change from baseline to Day 1 of Weeks 1, 2, 3, 6, 9 and 12 and on Week 24 then Day 1 of every 12 weeks and Final Visit.|Safety: Multiple Gated Acquisition (MUGA) will be assessed at specified time points as a measure of safety., MUGA, Change from baseline to every 12 weeks|Safety: Clinical Lab Tests will be performed for each participant as a safety measure., Chemistry, hematology, urinalysis lab tests will be measured and recorded on the case report forms. All clinically significant values will be followed by the investigator to a satisfactory clinical resolution., Change from baseline to Day 1 of Weeks 1, 2, 3, 6, 9 and 12 and on Week 24 then Day 1 of every 12 weeks and Final Visit
There are no secondary outcome measures specified for this study., There are no secondary outcome measures specified for this study., There are no secondary outcome measures specified for this study.
This study is designed to evaluate the safety of linifanib in subjects with advanced or metastatic solid tumors.